Twist Bioscience Launches cfDNA Library Preparation Kit For Liquid Biopsy Applications
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience Corporation (NASDAQ:TWST) launched the cfDNA Library Preparation Kit for liquid biopsy research, enhancing the detection of tumor variants in degraded or low DNA samples. This addition to Twist's portfolio aims to support the growing field of liquid biopsy applications, including cancer screening and monitoring for minimal residual disease (MRD). The kit is designed for high accuracy and sensitivity, capable of detecting rare allele variants with minimal sample input. It complements Twist's suite of tools for liquid biopsy assay development, including the Twist cfDNA Pan-Cancer Reference Standard v2.
February 06, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience's launch of the cfDNA Library Preparation Kit for liquid biopsy research could positively impact its stock price by enhancing its product portfolio and addressing a growing market need for accurate cancer detection and monitoring.
The launch of the cfDNA Library Preparation Kit positions Twist Bioscience at the forefront of liquid biopsy research, a rapidly growing field. By offering a solution that improves the detection of tumor variants, especially in early disease stages, TWST is likely to see increased interest from the research community. This innovation could lead to higher product sales and potentially increase the company's market share in the biotechnology sector, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100